Immunocore (IMCR) vs Vor Biopharma (VOR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Immunocore (IMCR) has outperformed Vor Biopharma (VOR) over the past year, losing 14.1% versus a loss of 44.4%. Over five years, IMCR leads with a -22.6% price change compared with -93.9% for VOR. Immunocore is the larger company by market cap ($1.50 billion vs $1.13 billion), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMCR | VOR |
|---|---|---|
| Share price | $29.09 | $19.13 |
| Market cap | $1.50B | $1.13B |
| 1-day change | -1.09% | +1.86% |
| YTD return | -15.27% | +43.58% |
| 1-year return | -14.06% | -44.44% |
| 5-year return | -22.61% | -93.93% |
| P/E ratio (TTM) | — | 0.11 |
| EPS (TTM) | $-0.36 | $180.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $40.72 | $33.50 |
| 52-week low | $27.56 | $6.50 |
| Distance from 52-week high | -28.55% | -42.90% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +115.64% | +103.87% |
| Average volume | 447.09K | 992.56K |
| Shares outstanding | 51.50M | 59.16M |
| Employees | 524 | 76 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMCR has outperformed VOR by 30.4 percentage points over the past year.
About Immunocore
IMCR stock →Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 524 employees
About Vor Biopharma
VOR stock →Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 76 employees
IMCR vs VOR FAQ
Which is bigger, Immunocore or Vor Biopharma?
Immunocore (IMCR) is larger, with a market capitalization of $1.50B compared with $1.13B for Vor Biopharma (VOR).
Which stock has performed better over the past year, IMCR or VOR?
IMCR returned -14.06% over the past 12 months, compared with -44.44% for VOR (price return, excluding dividends). Past performance does not predict future results.
Are Immunocore and Vor Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.